Evidence map›Paper›PMID 32357861›Full record

ArticleBMC cancer2020

Evaluation of the expression levels of BRAF

Tien Viet Tran, Kien Xuan Dang, Quynh Huong Pham, Ung Dinh Nguyen, Nhung Thi Trang Trinh, Luong Van Hoang, Son Anh Ho, Ba Van Nguyen, Duc Trong Nguyen, Dung Tuan Trinh and 5 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Tien Viet Tran103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.
Kien Xuan DangMinerva Foundation Institute for Medical Research, Helsinki, Finland.
Quynh Huong PhamDepartment of Genomics and Cytogenetics, Institute of Biomedicine and Pharmacy (IBP), Vietnam Military Medical University, 222 Phung Hung street, Ha Dong district, Hanoi, Vietnam.
Ung Dinh NguyenDepartment of Genomics and Cytogenetics, Institute of Biomedicine and Pharmacy (IBP), Vietnam Military Medical University, 222 Phung Hung street, Ha Dong district, Hanoi, Vietnam.
Nhung Thi Trang TrinhDepartment of Genomics and Cytogenetics, Institute of Biomedicine and Pharmacy (IBP), Vietnam Military Medical University, 222 Phung Hung street, Ha Dong district, Hanoi, Vietnam.
Luong Van HoangInstitute of Biomedicine and Pharmacy (IBP), Vietnam Military Medical University, Hanoi, Vietnam.
Son Anh HoInstitute of Biomedicine and Pharmacy (IBP), Vietnam Military Medical University, Hanoi, Vietnam.
Ba Van NguyenOncology Centre, 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.
Duc Trong NguyenSchool of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam.
Dung Tuan TrinhPathology Department, 108 Military Central Hospital, Hanoi, Vietnam.
Dung Ngoc TranDepartment of Pathology, 103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam.
Arto OrpanaLaboratory of Genetics, HUSLAB, Helsinki University Central Hospital, Helsinki, Finland.
Ulf-Håkan StenmanDepartment of Clinical Chemistry, Medicum, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Jakob StenmanMinerva Foundation Institute for Medical Research, Helsinki, Finland.
Tho Huu HoMinerva Foundation Institute for Medical Research, Helsinki, Finland. hohuutho@vmmu.edu.vn.
Vietnam Military Medical University · VNMinerva Foundation · FI108 Military Central Hospital · VNHelsinki University Hospital · FIUniversity of Helsinki · FIVietnam National University, Hanoi · VN

Funding

National Foundation for Science and Technology Development 106-YS.06-2016.16
6 · The paper itself

Abstract

backgroundThe BRAF

methodsSixty-two patients with thyroid cancer and non-malignant thyroid disease were included in the study. Armed with an ultrasensitive technique for mRNA-based mutation analysis based on a two step RT-qPCR method, we analysed the expression levels of the mutated BRAF

resultsThe mRNA-based mutation detection assay enables detection of the BRAF

conclusionsThe expression levels of BRAF

Indexed as

MutationBiomarkers, TumorCarcinoma, PapillaryDNA Mutational AnalysisDNA, NeoplasmFemaleFollow-Up StudiesHumansMalePrognosisProto-Oncogene Proteins B-rafReal-Time Polymerase Chain ReactionRNA, MessengerThyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorBRAF protein, humanDNA, NeoplasmProto-Oncogene Proteins B-rafRNA, MessengerBRAF mutationDiagnosismRNA mutation assayThyroid cancer

Identifiers

PMID32357861
PMCPMC7195771
OpenAlexW3022757788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.